Loading news...
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.3 per share a year ago.
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference.
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across public and private biopharmaceutical companies.
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have given a strong buy recommendation
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY.
Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company.
/PRNewswire/ -- Equity-Insider.com News Commentary - The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered direct offering included the sale of 2,030,314 shares of common stock at $6.71 per share (issue price). Certain investors received pre-funded warrants to purchase up to 5,421,250 shares at $6.7099 each, which reflects the share price minus a nominal exercise cost of $0.0001 per share. The offering also included series warrants to buy up to 3,725,782 shares at $13.42 per share (2x issue price) and another 3,725,782 shares at $20.13 per share (3x issue price). The $6.71 purchase price represented a 30% premium over the Nasdaq Global Market price on January 9, 2026. All shares in the offering were sold by Foghorn. The gross proceeds from the offering were approximately $50 million (excluding any proceeds to be received upon exercise of the series warrants).
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Profitability This table compares Foghorn Therapeutics and
Shares of Foghorn Therapeutics Inc. (NASDAQ: FHTX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 133.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and ER+ breast cancer; IND-ready in 2026 Robust preclinical anti-tumor activity and favorable tolerability across hematological malignancies differentiate novel, Selective EP300 degrader from dual CBP/EP300 approaches Selective ARID1B degrader advancing towards in vivo proof of concept in 2026 with relevance in up to 5% of solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $180.3 million as of September 30, 2025 ; cash runway into 2028 CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended September 30, 2025.
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference.
Foghorn Therapeutics Inc. ( FHTX ) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs October 30, 2025 12:00 PM EDT Company Participants Karin Hellsvik - Chief of Staff to the CEO, VP of Corporate Affairs & Investor Relations Adrian H. Gottschalk - President, CEO & Director Steven Bellon - Chief Scientific Officer Alfonso Quintas-Cardama - Chief Medical Officer Conference Call Participants Gavin Clark-Gartner Steven Ionov Yuxi Dong - Jefferies LLC, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Yuan Zhi - B.